Abstract Search

ea0081ep764 | Pituitary and Neuroendocrinology | ECE2022

Clinical characteristics, treatment and outcomes of well-differentiated gastroenteropancreatic G3 NET

Opalinska Marta , Staszczak Anna Sowa , Kurzyńska Anna , Morawiec-Sławek Karolina , Stefańska Agnieszka , Hubalewska-Dydejczyk Alicja

Background: Although gastroenteropancreatic neuroendocrine tumors G3 (GEP-NET G3) and neuroendocrine cancers (GEP-NEC G3) are characterized in histopathological examination by Ki67>20% or >20 mitoses/10HPF their management and prognosis is substantially different. Despite the WHO introduces the novel well-differentiated neuroendocrine tumour of high grade (NET G3) classification in 2017 the clinical management of them is still challenging due to high NET G3 heterogenei...

0 shares

ea0073aep509 | Pituitary and Neuroendocrinology | ECE2021

Self-administration of long-acting somatostatin analogues in NET patients forced by the COVID-19 pandemic – does it affect the clinical outcome?

Opalinska Marta , Anna Kurzynska , Staszczak Anna Sowa , Joanna Palen-Tytko , Zwinczewska Helena , Karolina Morawiec-Slawek , Hubalewska-Dydejczyk Alicja

BackgroundSomatostatin analogues (SSA) (octreotide and lanreotide) are recommended as a first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of them are usually used in injection repeated every 4 weeks.The study objectiveWas to compare the way of SSA administration (injection performed by profession...

0 shares

Endocrine Abstracts

Clinical characteristics, treatment and outcomes of well-differentiated gastroenteropancreatic G3 NET

Self-administration of long-acting somatostatin analogues in NET patients forced by the COVID-19 pandemic – does it affect the clinical outcome?

BiosciAbstracts